Condition: Advanced NSCLC · Advanced Endometrial Cancer · Sponsor: Huabo Biopharm Co., Ltd.
This study is a multicenter, two-tumor, multi-cohort, dose-escalation and dose-expansion Phase Ib/II clinical trial of HB0025 combined with chemotherapy, consists of two phases: the dose escalation phase (Ib) and the dose expansion phase (II). 1. The dose escalation phase (Phase Ⅰb) The primary purpose is to determine the Maximum Tolerated Dose(MTD) and/or dose limiting toxicity (DLT) of HB0025 combined with chemotherapy. The dose escalation is carried out using the "3+3 dose escalation" principle. In the initial stage of the dose escalation process, the chemotherapy dose remains unchanged to explore the safety and tolerability of the currently confirmed safe doses of HB0025 as monotherapy at 10mg/kg, and 20mg/kg, combined with chemotherapy(Pemetrexed 500 mg/m² iv d1+Carboplatin AUC 5 iv d1) in the treatment of advanced non-squamous non-samll cell lung cancer(Non-sq-NSCLC), and combined with chemotherapy( Paclitaxel 175 mg/m² iv d1+ Carboplatin AUC 5 iv d1 ) in advance Endometrial carcinoma(EC). After completing the first cycle of treatment (DLT evaluation period), if the investigator determines that the subject may benefit from the combined treatment, the subject will continue the treatment cycles (2nd to 4th/5th/6th cycle of HB0025 combined with chemotherapy); if there is no disease progression and no intolerable toxicity, the subject can continue to receive the maintenance treatment with HB0025 + pemetrexed (for non-sq NSCLC) or HB0025 alone (for EC, sq NSCLC), until …
This description comes directly from the study's public registry record.
Caicun Zhou, PhD. · +8613301825532 · caicunzhoudr@163.com
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Hebei University / School of Clinical Medicine | Baoding, Hebei, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First People'S Hospital of Lianyungãng | Lianyungang, Jiangsu, China | Recruiting |
| Liaoning Cancer Hospital＆Institute | Shenyang, Liaoning, China | Recruiting |
| Central Hospital Affiliated to Shandong First Medical University | Jinan, Shandong, China | Recruiting |
| Linyi Cancer Hospital | Linyi, Shandong, China | Recruiting |
| Weifang People'S Hospital | Weifang, Shandong, China | Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanxi Cancer hospital | Taiyuan, Shanxi, China | Recruiting |
| The First Affiliated Hospitalof Xi'an Jiaotong University | Xi’an, Shanxi, China | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06758557